54
Participants
Start Date
February 3, 2021
Primary Completion Date
January 22, 2024
Study Completion Date
January 22, 2024
INCB106385
INCB106385 will be administered orally QD
INCMGA00012
INCMGA0012 will be administered IV once every 4 weeks (Q4W)
Columbia University Medical Center, New York
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh, Pittsburgh
Irccs Istituto Clinico Humanitas, Rozzano
University of Maryland-Greenebaum Cancer Center, Baltimore
Fundacion Jimenez Diaz University Hospital, Madrid
Hospital Universitario 12 de Octubre, Madrid
Centro Integral Oncologico Clara Campal, Madrid
Clinica Universidad de Navarra (Cun), Pamplona
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse
Institut Bergonie, Bordeaux
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma), Verona
A.O.U. Di Modena - Policlinico, Modena
Md Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics, San Antonio
Istituto Nazionale Tumori Irccs Fondazione Pascale, Naples
Cedars-Sinai Medical Center, West Hollywood
Institut Gustave Roussy, Villejuif
Dana Farber Cancer Institute, Boston
Cliniques Universitaires Ucl Saint-Luc, Brussels
Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven
Hospital General Universitario Vall D Hebron, Barcelona
Cambridge University Hospitals Nhs Foundation Trust, Cambridge
University of Glasgow, Glasgow
Guys and St Thomas Nhs Foundation Trust, London
Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London
The Christie Nhs Foundation Trust Uk, Manchester
Lead Sponsor
Incyte Corporation
INDUSTRY